Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2022,
VistaGen Therapeutics received$0.02 Mil more from issuing new shares than it paid to buy back shares.
It received$0.00 Mil from issuing more debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$0.00 Mil on other financial activities.
In all, VistaGen Therapeutics
earned$0.02 Mil on financial activities for the
three
months ended in Mar. 2022.
VistaGen Therapeutics Cash Flow from Financing Historical Data
The historical data trend for VistaGen Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Cash Flow from Financing
16.52
17.42
4.01
114.10
10.48
VistaGen Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Cash Flow from Financing
4.09
0.99
7.35
2.12
0.02
VistaGen Therapeutics Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
VistaGen Therapeutics's Cash from Financing for the fiscal year that ended in Mar. 2022 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
VistaGen Therapeutics's issuance of stock for the
three
months ended in Mar. 2022 was $0.02 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
VistaGen Therapeutics's repurchase of stock for the
three
months ended in Mar. 2022 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
VistaGen Therapeutics's net issuance of debt for the
three
months ended in Mar. 2022 was $0.00 Mil.
VistaGen Therapeutics received$0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
VistaGen Therapeutics's net issuance of preferred for the
three
months ended in Mar. 2022 was $0.00 Mil.
VistaGen Therapeutics paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
VistaGen Therapeutics's cash flow for dividends for the
three
months ended in Mar. 2022 was $0.00 Mil.
VistaGen Therapeutics received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
VistaGen Therapeutics's other financing for the
three
months ended in Mar. 2022 was $0.00 Mil.
VistaGen Therapeutics received$0.00 Mil on other financial activities.
VistaGen Therapeutics Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.01(0.9%) Volume: 900,049 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
